Gastric fibroblasts specifically stimulated the growth of scirrhous gastric cancer cells, but not that of welldifferentiated adenocarcinoma cells. The growth factor(s) produced from gastric fibroblasts were then partially purified and characterised. The growth-promoting factor(s) had apparent molecular weights of 10 000 dalton and was sensitive both to heat and proteinase treatment. No inhibition for the factor(s) was achieved with defined anti-growth factor antibodies. In this study, differential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts were shown. Rapid proliferation of scirrhous gastric carcinoma should be partly controlled by orthotopic fibroblasts. The growth factor(s) from gastric fibroblasts, which was distinct from various defined growth factors such as epidermal growth factor (EGF), basic fibroblast growth factor (b-FGF), transforming growth factor-a (TGF-a), keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF), insulin-like growth factor I (IGF-I), hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF) and transforming growth factor ,B1 (TGF-,B1) may play an important role in the progression of scirrhous gastric cancer cells.
Human scirrhous gastric carcinoma (diffusely infiltrating carcinoma or Borrman's type IV carcinoma) is characterised by cancer cell infiltration and proliferation with extensive fibrosis in the stroma (Tahara, 1990) . Although the prognosis of gastric cancer has recently improved, that of scirrhous gastric cancer has not (Kiyasu et al., 1981) . One of the reasons for the poor prognosis of this type of cancer is the difficulty of diagnosing it at an early stage, in part because of the rapid proliferation of the cancer cells. When scirrhous gastric cancer cells invade into submucosa of stomach, the cancer cells proliferate rapidly with fibrosis. The mechanisms responsible for the rapid proliferation are not understood clearly. The typical histological findings of scirrhous gastric carcinoma suggest that its development may be controlled by intercellular interactions between the cancer cells and the stroma cells such as fibroblasts. Recently, several studies have been published on the effect of fibroblasts on the production of the extracellular matrix of gastric cancer cells (Naito et al., 1984; Yamamoto et al., 1990) . However, there has been no published report about the growth effect of gastric fibroblasts on scirrhous gastric cancer cells. Therefore, we examined the growth interaction between gastric cancer cells and fibroblasts derived from different organs, and partly purified and characterised a growth factor(s) for scirrhous gastric carcinoma.
Materials and methods
Cell types and cell culture The human gastric cancer cell lines, OCUM-2M (poorly differentiated adenocarcinoma) (Yashiro et al., 1995) , OCUM-1 (poorly differentiated adenocarcinoma), KATO- III (signet-ring cell carcinoma) (Sekiguchi et al., 1978) , (Hojo, 1977) , (Hojo, 1977) , were cultivated in medium (see below) in a 100-mm culture dish (Falcon, Lincoln Park, NJ, USA), and incubated at 37°C in a humidified atmosphere of 5% carbon dioxide in air. OCUM-2M, OCUM-1 and KATO-III were derived from scirrhous gastric carcinoma.
Human fibroblast cell lines were obtained from various organs. Original organ of each fibroblast cell line is presented in Table I . A fibroblast cell line, NF-8, and a scirrhous gastric cancer cell line, OCUM-2M, were obtained from the same patient (Yashiro et al., 1994) . NF-1, NF-Eso, NF-Je and NF-Co were obtained from the same patient. The other fibroblast cell lines were derived from different patients. HS-27F was obtained from the American Type Culture Collection (Rockville, MD, USA), and the other fibroblast cell lines were derived from normal tissues of each organ in our laboratory, as follows. Briefly, each tissue specimen was excised under aseptic conditions and minced with forceps and scissors. Pieces of each tissue were cultivated in medium in a 100-mm culture dish (Falcon) and incubated in humidified incubators at 37°C in an atmosphere of 5% carbon dioxide and 95% air. The fibroblasts gradually grew in a monolayer. When confluent, the fibroblasts were collected and transferred to another culture dish every 5-7 days. The fibroblast origin was verified by immunostaining with two monoclonal antibodies against vimentin and human fibroblast (Dako, Glostrup, Denmark).
The culture medium was composed of Dulbecco's modified Eagle medium (DMEM) (Bioproducts, Walkersville, MD, USA) with 2% heat-inactivated fetal calf serum (FCS) (Gibco, Grand Island, NY, USA), 100 IU ml-' penicillin (ICN Biomedicals, Costa Mesa, CA, USA), 100 Mug ml-' streptomycin (ICN Biochemicals), 2 mM glutamine (Bioproducts) and 0.5 mm sodium pyruvate (Bioproducts). (Industrial D; Coulter Electronics, Luton, UK) . To determine the optimal concentration of SF-CM for its growthpromoting activity, the kinetics and serum dependency of the activity produced from NF-8 cells were examined by culturing OCUM-2M cells. OCUM-2M cells were cultured in 24-well plates for 3 days in the presence of varying concentrations of SF-CM from NF-8 cells. Since the activity for OCUM-2M was evident following the addition of 25% SF-CM with 1-2% FCS (see Figure 1) 30 min. The susceptibility of the activity to proteases was examined by incubation of the SF-CM with 1 unit ml-' of proteases, trypsin (Sigma, St Louis, MO, USA), cx-chymotrypsin (Sigma), or proteinase K (Sigma) at 370C for 24 h. All samples were passed through filters (Kurabo). To determine whether the growth-promoting factor possessed heparin affinity, we examined the activity of SF-CM loaded onto the heparin affinity column ECHONO-Pac heparin cartridge (Bio-Rad, Richmond, CA, USA). Ion-exchange chromatography The SF-CM from NF-8 was applied to a TSK-gel DEAE-5PW column (75 x 7.5 mm; Tosoh, Tokyo, Japan) equilibrated with PBS. The column was washed with 20 ml PBS and the bound protein was eluted with a linear gradient of 0-0.8 M sodium chloride in the PBS. Eluted protein was detected by UV absorption at 280 nm. All manipulations were carried out at room temperature. Aliquots of 250,l of each fraction were added to 750 pl of OCUM-2M cell suspension (1 x 104 cells per well) with 2% FCS in each well of 24-well dishes, and growth-promoting activity was determined by calculating the number of cancer cells. Active fractions (20 ml) were then combined and concentrated to about 2 ml by ultrafiltration.
Gel filtration chromatography
The concentrated active fractions were applied to a TSK-gel G2000SWXL column (300 x 7.5 mm; Tosoh) equilibrated with PBS. The fractions were collected at a flow rate of 1 ml min-'. (Yoshida et al., 1989 (Yoshida et al., , 1990 Yasui et al., 1988; Tanimoto et al., 1991; Hattori et al., 1994; Shibamoto et al., 1992; Ito et al., 1992) on the growth of OCUM-2M cells. An aliquot of 1 ml of OCUM-2M cell suspension (1.0 x 104 cells ml-') was inoculated into each well of 24-well plates (Falcon) with various concentrations of the defined growth factors, and incubated. The number of OCUM-2M cells was counted at various time points.
Effect of anti-growth factor antibodies on the growth activity of conditioned medium from fibroblasts We used neutralising antibodies for several growth factors including anti-human EGF antibody (Oncogene Science, Uniondale, NY, USA), anti-human b-FGF antibody (Wako, Tokyo, Japan) (Hori et al., 1991), anti-TGF-a antibody (Pepro Tec), anti-HGF antibody (Sigma), rabbit IgG standard (Zymed, San Francisco, CA, USA) and mouse IgG standard (Tago, Burlingame, CA, USA). These antibodies were reconstituted in 0.1 g BSA per 100 ml of serum-free medium. Effect of the neutralising antibodies against their respective ligands was examined in experi--1099 mental study (see Table III ). Antibody solutions of 4, 20, 100 and 400 ,g ml-I were prepared and mixed 1: 1 (v/v) with the peak growth activity fraction 22 by highperformance liquid chromatography (HPLC) (see Figure  3b) . A 500 Ml portion of OCUM-2M cell suspension (1 x 104 cells per well) with 2% FCS was inoculated into each well of 24-well plates (Falcon). Antibody solutions (500 ,ul) were added to each well and incubated. Final solutions contained 25% fraction sample and antibody concentrations of 1, 5, 25 or 100 Mg ml-'. After 3 days the number of OCUM-2M cells was counted. Serum-free medium instead of active fraction was used as a control.
Statistical analysis Data were analysed statistically using Student's t-test. A Pvalue less than 0.05 was considered statistically significant.
Results
Growth-promoting activity of serum-free conditioned medium from fibroblasts for various gastric cancer cells The activity for OCUM-2M cells was evident following the addition of 25% SF-CM with 1-2% FCS (Figure 1) graphy aSerum-free conditioned medium from NF-8 was subjected to different treatments as described in Materials and methods. The addition of the SF-CM. The SF-CM from gastric fibroblasts (NF-1, NF-8) significantly increased the number of scirrhous gastric cancer cells (OCUM-2M, OCUM-1, KATO-I1I) after 60 h in culture but not that of well-differentiated adenocarcinoma cells (MKN-28, MKN-74) . The SF-CM from foreskin fibroblasts (HS-27F) did not increase the number of any cancer cells (Figure 2) . The SF-CM from orthotopic fibroblasts (NF-1, NF-8) specifically stimulated the DNA synthesis of scirrhous gastric cancer cells by 130-180% compared with control, but not well-differentiated adenocarcinoma cells. The SF-CM from various ectopic fibroblasts did not stimulate the DNA synthesis of any type of gastric cancer cells (Figure 3 ). Characterisation of the growth-promoting activity The effects of various treatments on the growth-promoting activity of the conditioned medium are shown in Table II . Protein concentrations in SF-CM from fibroblasts were measured by a Bio-Rad protein assay kit (Bio-Rad, Richmond, VA, USA) using BSA as a standard. Protein concentration in each SF-CM was 40.6-49.3 ig ml-' per 2 x 106 cells. The activity was partially lost when heated at 56°C for 30 min and completely lost when heated at 80°C for 10 min. Treatment with trypsin, a-chymotrypsin, or proteinase K also destroyed the activity completely. The growthpromoting activity of SF-CM was retained even after heparin chromatography (Table II) .
Purification of the growth-promoting activity The SF-CM from NF-8 was applied to a TSK-gel DEAE-5PW column. Peak activity was eluted at 160 mM sodium chloride (Figure 4a ). The active fractions 9 and 10 were concentrated and applied to a TSK-gel G2000SWXL column. A peak of growth-promoting activity was observed in fraction 22. From calculation of molecular weight of the polypeptide using the standard samples, it was estimated that the apparent molecular weight of the major peak was 10 000 dalton ( Figure 4b ). The growth of MKN-28 cells was not stimulated following the addition of fraction 22 (data not shown).
Effect of defined growth factors on the growth of OCUM-2M cells To identify possible mitogens involved in OCUM-2M cell growth, we investigated the dose -response relationship between OCUM-2M cells and defined growth factors, including EGF, VEGF, TGF-ac, IGF-I, KGF, b-FGF, PDGF-AA, HGF and TGF-1. OCUM-2M cells were cultured with these growth factors in concentrations ranging from 0.1-100 ng ml -. EGF, TGF-oc, VEGF, KGF and b-FGF significantly stimulated OCUM-2M cell growth in concentrations ranging from 10 to 100 ng ml-' after 72 h culture. IGF-I, PDGF and HGF had no significant effect on the growth of OCUM-2M cells. TGF-,B decreased the growth of OCUM-2M cells (Figure 5a ). The growth effect was evident after 72 h culture (Figure 5b ).
Effect of anti-growth factor antibodies on the growth activity of conditioned medium from gastric fibroblasts To determine the relation between the growth activity of SF-CM and the defined growth factors which stimulated OCUM-2M cell growth, we tested whether neutralising antibodies against EGF, b-FGF and PDGF-AA were able to neutralise the growth-stimulating activity of the HPLC fraction 22. Bioactivity of each antibody in OCUM-2M cells was demonstrated in Table III . The growth activity of the fraction was not inhibited by any neutralising antibody (Table IV) . al., 1990; Yasui et al., 1988; Tanimoto et al., 1991; Hattori et al., 1994; Shibamoto et al., 1992; Ito et al., 1992; Yoshida et al., 1989) . Most scirrhous gastric cancer cell lines are known to be stimulated by EGF, b-FGF and KGF (Yoshida et al., 1990; Yasui et al., 1988; Tanimoto et al., 1991; Hattori et al., 1994) . The growth of OCUM-2M cells was also stimulated by EGF, TGF-ax, VEGF, b-FGF and KGF, but not IGF-I, PDGF, HGF and TGF-fJ. In general, fibroblasts have been reported to produce growth factors (Ankrapp et al., 1993; Hlatky et al., 1994; Lawrence et al., 1984; Mooradian et al., 1992; Mukai et al., 1989) . We examined whether any of the defined growth factors including EGF, VEGF, TGF-cL, b-FGF and KGF, was the active factor in the conditioned medium from gastric fibroblasts. However, the growth activity of the conditioned medium was not decresed by neutralising antibody against EGF, TGF-a, b-FGF and VEGF. In addition, no reactivity with these antibodies in the active fraction was shown by immunoblotting (data not shown). Conditioned medium loaded onto a heparin affinity column had the growthpromoting activity equal to that of the conditioned medium before loading, which indicates that the heparin affinity growth factors such as KGF, b-FGF and VEGF are distinct from the growth activity present in SF-CM. Recently, more than fifty cell growth factors have been evident. In this study, only nine growth factors were examined; however, these factors were almost included in all factors which had been reported previously to be associated with the growth of gastric cancer cells. These findings suggest that the growth factor(s) produced by gastric fibroblasts might be different from the defined factors known to be associated with the progression of gastric carcinoma.
In conclusion, rapid proliferation of scirrhous gastric carcinoma should be partly controlled by gastric fibroblasts. There has been no previous report of a growth factor with growth-promoting activity which depends on the histological type of gastric cancer cells. The growth factior(s) produced by gastric fibroblasts might be a unique factor(s) and may play an important role in the progression of scirrhous gastric cancer.
Abbreviations DMEM, Dulbecco's modified Eagle medium; PBS, Dulbecco's phosphate-buffered saline; FCS, fetal calf serum; BSA, bovine serum albumin; EGF, epidermal growth factor; b-FGF, basic fibroblast growth factor; KGF, keratinocyte growth factor; VEGF, vascular endothelial cell growth factor; TGF-a, transforming growth factor alpha; IGF-I, insulin growth factor-I; PDGF-AA, platelet-derived growth factor AA homodimer; HGF, hepatocyte growth factor; TGF-,B1, transforming growth factor-fI; HPLC, high-performance liquid chromatography.
